Actinium Pharmaceuticals, Inc.

NYSEAM:ATNM Stock Report

Market Cap: US$37.4m

Actinium Pharmaceuticals Management

Management criteria checks 2/4

Actinium Pharmaceuticals' CEO is Sandesh Seth, appointed in Jun 2017, has a tenure of 7.5 years. total yearly compensation is $4.70M, comprised of 15% salary and 85% bonuses, including company stock and options. directly owns 0.017% of the company’s shares, worth $6.46K. The average tenure of the management team and the board of directors is 3.3 years and 11.1 years respectively.

Key information

Sandesh Seth

Chief executive officer

US$4.7m

Total compensation

CEO salary percentage15.0%
CEO tenure7.5yrs
CEO ownership0.02%
Management average tenure3.3yrs
Board average tenure11.1yrs

Recent management updates

Recent updates

Actinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth Plans

Dec 28
Actinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth Plans

CEO Compensation Analysis

How has Sandesh Seth's remuneration changed compared to Actinium Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$41m

Jun 30 2024n/an/a

-US$43m

Mar 31 2024n/an/a

-US$46m

Dec 31 2023US$5mUS$705k

-US$49m

Sep 30 2023n/an/a

-US$50m

Jun 30 2023n/an/a

-US$46m

Mar 31 2023n/an/a

-US$39m

Dec 31 2022US$4mUS$665k

-US$33m

Sep 30 2022n/an/a

-US$30m

Jun 30 2022n/an/a

-US$27m

Mar 31 2022n/an/a

-US$25m

Dec 31 2021US$2mUS$615k

-US$25m

Sep 30 2021n/an/a

-US$23m

Jun 30 2021n/an/a

-US$22m

Mar 31 2021n/an/a

-US$22m

Dec 31 2020US$2mUS$578k

-US$22m

Sep 30 2020n/an/a

-US$20m

Jun 30 2020n/an/a

-US$21m

Mar 31 2020n/an/a

-US$22m

Dec 31 2019US$1mUS$561k

-US$22m

Sep 30 2019n/an/a

-US$24m

Jun 30 2019n/an/a

-US$23m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$1mUS$545k

-US$24m

Sep 30 2018n/an/a

-US$22m

Jun 30 2018n/an/a

-US$23m

Mar 31 2018n/an/a

-US$25m

Dec 31 2017US$306kUS$306k

-US$27m

Compensation vs Market: Sandesh's total compensation ($USD4.70M) is above average for companies of similar size in the US market ($USD646.54K).

Compensation vs Earnings: Sandesh's compensation has increased whilst the company is unprofitable.

CEO

Sandesh Seth (60 yo)

7.5yrs

Tenure

US$4,704,999

Compensation

Mr. Sandesh C. Seth, M.S., MBA has been Chief Executive Officer of Actinium Pharmaceuticals, Inc. since June 5, 2017. Mr. Seth serves as the Head of Healthcare Investment Banking at Laidlaw & Company (UK)...

Leadership Team

NamePositionTenureCompensationOwnership
Sandesh Seth
Chairman & CEO7.5yrsUS$4.70m0.017%
$ 6.5k
Steven O'Loughlin
CFO & Corporate Secretary7.6yrsUS$1.49m0.0038%
$ 1.4k
Paul Diamond
Vice President of Patent & Legal Counsel3.3yrsno datano data
Avinash Desai
Chief Medical Officer4.1yrsno datano data
Jenny Hsieh
Chief Strategy Officer2.2yrsno datano data
Sunitha Lakshminarayanan
Senior VP2.2yrsno datano data
Caroline Yarbrough
Chief Commercial Officer2.1yrsno datano data
Lynn Bodarky
Chief Business Officer1.1yrsno datano data
J. Simeon
Executive Director of Quality Assurance8.3yrsno datano data
Madhuri Vusirikala
Vice President of Clinical Development BMT & Cellular Therapyno datano datano data

3.3yrs

Average Tenure

58yo

Average Age

Experienced Management: ATNM's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sandesh Seth
Chairman & CEO12.8yrsUS$4.70m0.017%
$ 6.5k
Richard Steinhart
Independent Director11.1yrsUS$313.00k0.0010%
$ 378.1
David Scheinberg
Member of Clinical Advisory Boardno datano datano data
Hagop M. Kantarjian
Member of Clinical Advisory Boardno datano datano data
Richard Wahl
Member of Clinical Advisory Boardno datano datano data
Ajit S. Shetty
Independent Director7.8yrsUS$308.50k0.0024%
$ 909.7
C. Nicholson
Lead Independent Director16.9yrsUS$313.00k0.0011%
$ 400.6
Joseph Jurcic
Chairman of Clinical Advisory Boardno datano datano data
Elihu Estey
Member of Clinical Advisory Boardno datano datano data
John Pagel
Chairman of Scientific Advisory Board & Member of Clinical Advisory Boardno datano datano data
Alexander Perl
Member of Clinical Advisory Boardno datano datano data
Sergio Giralt
Member of Scientific Advisory Board10.5yrsno datano data

11.1yrs

Average Tenure

68yo

Average Age

Experienced Board: ATNM's board of directors are seasoned and experienced ( 11.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 06:23
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Actinium Pharmaceuticals, Inc. is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yuan ZhiB. Riley Securities, Inc.
George ZavoicoB. Riley Securities, Inc.
John NewmanCanaccord Genuity